Tülay Canda1, Ekrem Yavuz2, Necmettin Özdemir3, Sennur İlvan4, Serpil Sak Dizbay5, Merih Güray Durak1, Sıtkı Tuzlalı2, Osman Zekioğlu3, Atakan Demir4, Handan Onur5, Kasım Üstündağ6, Burçe Göktaş6. 1. Department of Pathology, Dokuz Eylül University School of Medicine, İzmir, Turkey. 2. Department of Pathology, İstanbul University, İstanbul School of Medicine, İstanbul, Turkey. 3. Department of Pathology, Ege University School of Medicine, İzmir, Turkey. 4. Department of Pathology, İstanbul University, Cerrahpaşa School of Medicine, İstanbul, Turkey. 5. Department of Pathology, Ankara University School of Medicine, Ankara, Turkey. 6. Clinical Research, Roche Preparations San. Inc., İstanbul, Turkey.
Abstract
OBJECTIVE: As patients with increased human epidermal growth factor receptor (HER2) overexpression are more likely to benefit from trastuzumab treatment, the accuracy of HER2 receptor status in breast cancer patients is significant for appropriate disease management. However, this assessment is not harmonized and results may be highly variable between centers. The aim of this study was to investigate the degree of interlaboratory variability in the results of HER2 expression reported by 5 participating centers and to assess the concordance between these centers and a reference laboratory.Materials and Methods: A total of 30 breast cancer samples were tested and scored for HER2 expression using immunohistochemical method in 5 centers from Turkey and in a reference laboratory from Netherlands (Academic Medical Center, Amsterdam). All the participating centers had an experience of more than 10 years regarding the HER2 testing. The results were compared both among the centers and with the reference laboratory. RESULTS: When the concordance of participating centers and the reference laboratory was evaluated regarding negative (0-1+), equivocal 2(+) and positive 3(+) classification of HER2 immunostaining, the highest concordance was found in Center-A, and the lowest in Center-C (Kendall's tau-b concordance coefficient 0.911 and 0.724, respectively). The concordance of the centers with reference laboratory was 80.0% both in equivocal and positive samples, while it increased up to 91.8% in negative samples. CONCLUSIONS: This study showed that in general there is sufficiently good agreement between the reference laboratory and the participating centers for immunohistochemical HER2 assessment.
OBJECTIVE: As patients with increased human epidermal growth factor receptor (HER2) overexpression are more likely to benefit from trastuzumab treatment, the accuracy of HER2 receptor status in breast cancer patients is significant for appropriate disease management. However, this assessment is not harmonized and results may be highly variable between centers. The aim of this study was to investigate the degree of interlaboratory variability in the results of HER2 expression reported by 5 participating centers and to assess the concordance between these centers and a reference laboratory.Materials and Methods: A total of 30 breast cancer samples were tested and scored for HER2 expression using immunohistochemical method in 5 centers from Turkey and in a reference laboratory from Netherlands (Academic Medical Center, Amsterdam). All the participating centers had an experience of more than 10 years regarding the HER2 testing. The results were compared both among the centers and with the reference laboratory. RESULTS: When the concordance of participating centers and the reference laboratory was evaluated regarding negative (0-1+), equivocal 2(+) and positive 3(+) classification of HER2 immunostaining, the highest concordance was found in Center-A, and the lowest in Center-C (Kendall's tau-b concordance coefficient 0.911 and 0.724, respectively). The concordance of the centers with reference laboratory was 80.0% both in equivocal and positive samples, while it increased up to 91.8% in negative samples. CONCLUSIONS: This study showed that in general there is sufficiently good agreement between the reference laboratory and the participating centers for immunohistochemical HER2 assessment.
Entities:
Keywords:
HER2; Immunohistochemistry; breast cancer; diagnosis
Authors: Marios A Gavrielides; Brandon D Gallas; Petra Lenz; Aldo Badano; Stephen M Hewitt Journal: Arch Pathol Lab Med Date: 2011-02 Impact factor: 5.534
Authors: Patrick L Fitzgibbons; Deborah A Dillon; Randa Alsabeh; Michael A Berman; Daniel F Hayes; David G Hicks; Kevin S Hughes; Sharon Nofech-Mozes Journal: Arch Pathol Lab Med Date: 2013-11-15 Impact factor: 5.534
Authors: D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich Journal: Science Date: 1989-05-12 Impact factor: 47.728
Authors: Soonmyung Paik; John Bryant; Elizabeth Tan-Chiu; Edward Romond; William Hiller; Kyeongmee Park; Ann Brown; Greg Yothers; Steve Anderson; Roy Smith; D Lawrence Wickerham; Norman Wolmark Journal: J Natl Cancer Inst Date: 2002-06-05 Impact factor: 13.506
Authors: T A Thomson; M M Hayes; J J Spinelli; E Hilland; C Sawrenko; D Phillips; B Dupuis; R L Parker Journal: Mod Pathol Date: 2001-11 Impact factor: 7.842
Authors: S Paik; J Bryant; C Park; B Fisher; E Tan-Chiu; D Hyams; E R Fisher; M E Lippman; D L Wickerham; N Wolmark Journal: J Natl Cancer Inst Date: 1998-09-16 Impact factor: 13.506